This activity has expired. CME/CE credit is no longer available and the following content may not be up-to-date.
Start the program by clicking on the Start Program icon at the bottom of this page.
Program Title
Update: Discussion of 2009 ASCO Meeting Neuro-Oncology Highlights
Release Date: July-08-09
Credit Expiration Date: July-08-10
Program Developer/Facilitator
Medical Communications Media, Inc.
Target Audience
This program, developed by experts in neuro-oncology, radiation oncology, and neurosurgery, has been designed for physicians who interact with oncology patients.
Credit Hours
CME 1.0
Medium
Video Roundtable
Program Description
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHYSICIANS ONLY.
The 2009 ASCO Annual Meeting, held in late June in Orlando, Florida, offered attendees a comprehensive view of key research and clinical advances in cancer treatment. In this 1-hour, CME-certified, video discussion, Marc Chamberlain, MD, reviews brain cancer highlights from the conference with Martin van den Bent, MD, PhD, and David Reardon, MD. This intriguing interchange between these world-renowned leaders in neuro-oncology focuses on key research presented on primary and adjuvant treatment for glioblastoma. Offering an overview and critique of some of the most pertinent studies, the faculty provide data that is valuable to both researchers and practitioners.
For more information go to http://www.asco.org/ASCOv2/Meetings/Abstracts
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Evaluate emerging concepts in the diagnosis and prognosis of brain tumors.
2.
Discuss study findings regarding the efficacy and safety of adjuvant bevacizumab for newly diagnosed glioblastoma.
3.
List other adjuvant chemotherapies being tested as front-line treatments for glioblastoma in combination with the current standard of care regimen.
4.
Describe emerging therapies being tested for recurrent glioblastoma.
Faculty
Moderator/Interviewer
Marc Chamberlain, MD
Professor, Departments of Neurology and Neurological Surgery
University of Washington
Seattle, WA
David A. Reardon, MD
Associate Professor
Department of Surgery
Duke University Medical Center
Durham, NC
Martin J. van den Bent, MD, PhD
Professor in Neuro-Oncology
Head, Neuro-Oncology Unit
Daniel den Hoed Cancer Center
Erasmus University Medical Center
Rotterdam, The Netherlands
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Chamberlain
discloses product consultation and speakers’ bureau participation for Schering-Plough and Genentech.
Dr. Reardon
discloses speaker's bureau participation for Schering-Plough and Genentech, and product consultation for Genentech, Adnexus Therapeutics, and Bradmer Pharmaceuticals.
Dr. van den Bent
indicates he has no actual or potential conflict of interest to this program.
This educational activity may contain discussion of investigational uses of pharmaceutical agents or surgical devices. Some of these agents/devices may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support Statements
Supported through an educational grant from Schering-Plough Corporation.
Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.0
AMA PRA Category 1 Credit
™
. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity should take approximately 60 minutes to complete. Credit is awarded to participants who view the presentation, score 80% or better on the post-test and complete an evaluation.
Certificate Fee
$0.00
Disclaimer
©2009 Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the video recording are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.
Related Programs
Title
Audience
Medium
